Branded Ingredients · Other
Advasorb Vitamin D (Cholecalciferol)
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Advasorb Vitamin D is an enhanced absorption form of cholecalciferol that supports calcium homeostasis through vitamin D receptor activation. This proprietary formulation aims to improve bioavailability compared to standard vitamin D3 supplements.
Advasorb Vitamin D (Cholecalciferol) is a branded form of vitamin D3, a secosteroid essential for calcium regulation derived from the UVB irradiation (290-315 nm) of 7-dehydrocholesterol from animal lanolin or industrial synthesis. Production involves irradiating 7-dehydrocholesterol to form previtamin D3, which isomerizes to cholecalciferol upon warming, followed by purification via supercritical or liquid CO2 column chromatography.
No clinical trials, RCTs, or meta-analyses were found specifically for the Advasorb Vitamin D branded product. Evidence supporting cholecalciferol (vitamin D3) exists in general medical literature, but no PMIDs or specific study details were provided in the research dossier for this branded ingredient.
No clinically studied dosage ranges are available for Advasorb Vitamin D or its specific forms. General cholecalciferol dosing relies on external guidelines not specified in the research. Consult a healthcare provider before starting any new supplement.
Advasorb Vitamin D is a cholecalciferol (vitamin D3) supplement utilizing advanced absorption technology (typically a micellar or lipid-based delivery system designed to enhance bioavailability in individuals with fat malabsorption issues). **Active compound:** Cholecalciferol (vitamin D3), typically standardized at 1,000–4,000 IU (25–100 mcg) per soft capsule depending on product variant. **Bioactive form:** Cholecalciferol is a secosteroid prohormone; upon ingestion it is hydroxylated in the liver to 25-hydroxyvitamin D (calcidiol), then further hydroxylated in the kidneys to the active hormone 1,25-dihydroxyvitamin D (calcitriol). **Macronutrients:** Negligible calories, fat, protein, carbohydrates, and fiber per serving (trace lipid excipients only, typically <0.5 g fat from the solubilization matrix). **Micronutrients:** Primary micronutrient is vitamin D3; no significant amounts of other vitamins or minerals unless co-formulated. **Bioavailability notes:** The 'Advasorb' designation refers to a proprietary micellized or pre-solubilized lipid delivery system (often using polysorbate 80, medium-chain triglycerides, or similar surfactant-based matrices) designed to create water-dispersible micelles, bypassing the need for bile salt-dependent emulsification. This is particularly relevant for individuals with compromised fat absorption (e.g., cystic fibrosis, bariatric surgery, cholestatic liver disease, short bowel syndrome). Studies on micellized vitamin D3 formulations have demonstrated 2–5 fold higher absorption (as measured by serum 25(OH)D rise) compared to standard oil-based cholecalciferol in malabsorptive populations. In healthy individuals with normal fat absorption, the bioavailability advantage is more modest. Standard cholecalciferol bioavailability from oil-based supplements is approximately 55–99% in healthy adults; micellized forms aim to approach the upper range consistently regardless of digestive capacity. **Other excipients (typical):** Medium-chain triglycerides (MCT), polysorbate 80 or similar non-ionic surfactant, glycerin, purified water, gelatin or plant-based capsule shell. No significant protein, fiber, or additional mineral content.
Cholecalciferol undergoes 25-hydroxylation in the liver by CYP2R1 and CYP27A1 enzymes, forming 25(OH)D3. This metabolite is converted to active calcitriol (1,25(OH)2D3) in kidneys via 1α-hydroxylase, which binds vitamin D receptors to upregulate calcium-binding proteins and intestinal calcium absorption. Advasorb technology potentially enhances initial absorption through specialized delivery mechanisms.
While no specific clinical trials exist for the Advasorb brand, standard cholecalciferol studies demonstrate efficacy in correcting vitamin D deficiency and supporting bone health. Meta-analyses of vitamin D3 supplementation show 1000-4000 IU daily can raise 25(OH)D levels by 10-40 ng/mL depending on baseline status. Enhanced absorption formulations theoretically require lower doses to achieve equivalent serum levels, though head-to-head comparisons with Advasorb are lacking. Evidence strength relies on general cholecalciferol research rather than proprietary formulation data.
Vitamin D toxicity occurs above 10,000 IU daily long-term, causing hypercalcemia, kidney stones, and cardiac arrhythmias. Enhanced absorption formulations like Advasorb may theoretically increase toxicity risk at equivalent doses. Drug interactions include reduced absorption with orlistat and increased digitalis toxicity due to hypercalcemia. Pregnancy safety is established for doses up to 4000 IU daily, though enhanced absorption effects during pregnancy remain unstudied.
Based on the mechanism and research, Advasorb Vitamin D (Cholecalciferol) may support the following health areas. Each link goes to an evidence-ranked guide of the best ingredients for that concern.
Or jump to the curated Best Bone & Joint Health Stack → top 12 evidence-ranked ingredients.
